SOM Biotech signs letter of intent with Megapharm to commercialize SOM3355 in Israel and the Palestinian Authority

NEXT STORY
North America Biosimilars Market (2020 to 2030) – Trend Forecasts and Growth Opportunities
PREV STORY
Molecular Partners to Host Oncology Day (Virtual)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

author_avatar
NASDAQ Market News

Promising Treatment for Sepsis Enters Clinical Trials: A Pipeline Products Review by DelveInsight

author_avatar
NASDAQ Market News

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy ...

author_avatar
NASDAQ Market News